MDRNA, Inc. (MRNA) Announces Full Repayment of GE Capital Debt
More News related to GE
- GE Oil & Gas Supports European Growth with New Global Services Facility
- General Electric (GE) Increases Price on Single Tranche Bond to $475M from $400M - DJN
- GE Awarded $2MM to Develop Sensor for Geothermal Wells in the United States
- Option volume leaders today according to Track Data are: BAC GE C GS
- YM Krishna SSK Chooses GE Fanuc Intelligent Platforms' Proficy Process Systems for Renewable Energy Production
More News related to MRNA
- Morning Movers 11/13: CNIC, TSTC, NLST, AGO, SLI Higher; LIME, GMET, BIOF, DISK, MRGE, SSY Lower
- After-Hours Movers 11/12: TSTC, LXRX, MDSO Higher; DISK, MRNA, LIME, BBI, ESE, JWN Lower
- MDRNA (MRNA) Reports Q3 Loss of $0.17
- MDRNA, Inc. Receives NASDAQ Notification
- MDRNA, Inc. Announces Third Quarter 2009 Financial Results
MDRNA, Inc. (NASDAQ: MRNA) announced that it has repaid all of its remaining debt to General Electric (NYSE: GE) Capital Corporation (GECC) under the January 2009 Loan and Security Agreement.
"I am pleased we have met our commitment to shareholders to eliminate the Company's remaining term debt obligations prior to the start of the third quarter," stated J. Michael French, President and CEO. "In less than five months time, we retired a $5.5 million loan created to consolidate our GE Capital leases. The repayment of this loan removes all liens on our intellectual property, equipment and other assets, thus providing us maximum flexibility in establishing broad target and therapeutic-based pharma collaborations. By eliminating the remaining debt, we have significantly strengthened our balance sheet, enabling us to further capitalize on our strong science and broad intellectual property estate."
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
Related Categories
Corporate NewsStocks Mentioned
-0.17Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
ANALYSTS ON 'MRNA'
jimmy T on Aug 31, 2009 08:49 AMAFTER THREE CONSECUTIVE YEARS OF BEING DEAD WRONG ON THEIR TARGET PRICES, THEY STILL ARE ISSUING A $4.00 TARGET PRICE. WHY? THESE PEOPLE SHOULD BE INVESTIGATED! CLOSED $1.40 FRIDAY. MRNA-TODAY AUG.31,2009 Bid: 1.35 x 500 Ask: 1.62 x 100